Stephen A.  Trowbridge net worth and biography

Stephen Trowbridge Biography and Net Worth

Stephen A. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having served as Interim Chief Financial Officer since October 2019. Prior to his appointment as Chief Financial Officer, he served as the Company’s Senior Vice President and General Counsel. He joined AngioDynamics in June 2008 as Corporate Counsel. 

In addition to serving as the Company’s CFO and managing the finance functions,
Mr. Trowbridge also manages the Legal function on an interim basis. Mr. Trowbridge also oversees the Company’s clinical affairs, medical affairs and healthcare economics departments. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. 

Mr. Trowbridge began his career with Cadwalader, Wickersham & Taft LLP in the firm’s Mergers and Acquisitions and Securities Group. Mr. Trowbridge received a Bachelor of Science in Science and Technology Studies from Rensselaer Polytechnic Institute, a Juris Doctor from the University of Pennsylvania Law School, and a Master of Business Administration from Duke University’s Fuqua School of Business.

What is Stephen A. Trowbridge's net worth?

The estimated net worth of Stephen A. Trowbridge is at least $1.22 million as of October 8th, 2024. Mr. Trowbridge owns 172,711 shares of AngioDynamics stock worth more than $1,224,521 as of December 3rd. This net worth approximation does not reflect any other investments that Mr. Trowbridge may own. Additionally, Mr. Trowbridge receives an annual salary of $528,020.00 as CFO at AngioDynamics. Learn More about Stephen A. Trowbridge's net worth.

How old is Stephen A. Trowbridge?

Mr. Trowbridge is currently 50 years old. There are 7 older executives and no younger executives at AngioDynamics. The oldest executive at AngioDynamics is Mr. James C. Clemmer, CEO, President & Director, who is 60 years old. Learn More on Stephen A. Trowbridge's age.

What is Stephen A. Trowbridge's salary?

As the CFO of AngioDynamics, Inc., Mr. Trowbridge earns $528,020.00 per year. There are 2 executives that earn more than Mr. Trowbridge. The highest earning executive at AngioDynamics is Mr. James C. Clemmer, CEO, President & Director, who commands a salary of $982,920.00 per year. Learn More on Stephen A. Trowbridge's salary.

How do I contact Stephen A. Trowbridge?

The corporate mailing address for Mr. Trowbridge and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected]. Learn More on Stephen A. Trowbridge's contact information.

Has Stephen A. Trowbridge been buying or selling shares of AngioDynamics?

During the last ninety days, Stephen A. Trowbridge has bought $9,962.00 of AngioDynamics stock. Most recently, on Tuesday, October 8th, Stephen A. Trowbridge bought 1,700 shares of AngioDynamics stock. The stock was acquired at an average cost of $5.86 per share, with a total value of $9,962.00. Following the completion of the transaction, the chief financial officer now directly owns 172,711 shares of the company's stock, valued at $1,012,086.46. Learn More on Stephen A. Trowbridge's trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), and Stephen Trowbridge (CFO). Learn More on AngioDynamics' active insiders.

Are insiders buying or selling shares of AngioDynamics?

During the last twelve months, AngioDynamics insiders bought shares 5 times. They purchased a total of 32,568 shares worth more than $202,847.12. The most recent insider tranaction occured on October, 10th when SVP Warren Nighan Jr bought 100 shares worth more than $608.00. Insiders at AngioDynamics own 5.4% of the company. Learn More about insider trades at AngioDynamics.

Information on this page was last updated on 10/10/2024.

Stephen A. Trowbridge Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/8/2024Buy1,700$5.86$9,962.00172,711View SEC Filing Icon  
10/12/2022Buy1,083$13.82$14,967.0689,581View SEC Filing Icon  
1/12/2022Buy1,000$22.64$22,640.00View SEC Filing Icon  
8/11/2020Buy1,013$9.38$9,501.9460,273View SEC Filing Icon  
4/25/2016Sell12,940$12.30$159,162.0032,469View SEC Filing Icon  
See Full Table

Stephen A. Trowbridge Buying and Selling Activity at AngioDynamics

This chart shows Stephen A Trowbridge's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $7.09
Low: $6.97
High: $7.13

50 Day Range

MA: $6.87
Low: $5.88
High: $7.78

2 Week Range

Now: $7.09
Low: $5.26
High: $8.25

Volume

72,449 shs

Average Volume

518,619 shs

Market Capitalization

$288.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68